Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: Apr 7, 2010


Genetic Alliance last week announced the appointment of Ann Waldo as its senior counsel.

"This marks the first time in its 24-year history that Genetic Alliance has in-house counsel," Genetic Alliance said in a statement. Waldo will provide legal guidance to the non-profit genetics research and policy organization on issues, such as privacy, gene patenting, genetic discrimination, newborn screening, and health information technology.

Waldo is also a partner in the law firm of Oldaker, Belair & Wittie, LLP, where she specializes in legal issues dealing with privacy and information management, particularly with respect to the Health Insurance Portability and Accountability Act. Previously, Waldo was the chief privacy officer for Lenovo and she also served as the chief privacy officer at Hoffman-La Roche.

Silicon Kinetics announced two new members to its board of directors: Rick Brown, formerly the CEO of MicroCal, acquired by GE Healthcare; and Eric Topol, director of Scripps Translational Science Institute and chief academic officer of Scripps Health.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.